Prophylaxis with rivaroxaban against venous thromboembolism (VTE): a cost-consequence analysis from the Italian Healthcare Service perspective

Thromboprophylactic regimens based on rivaroxaban – a novel, oral, once-daily, direct Factor Xa inhibitor approved in the EU and Canada for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective total hip and total knee replacement (THR/TKR) surgery – were compared with subcutaneous enoxaparin (40 mg once daily) regimens in phase III randomized clinical trials in patients undergoing THR (RECORD1 and RECORD2) 1,2 or TKR (RECORD3) 3 In addition to the clinical benefits associated with reducing symptomatic VTE, significant economic benefits may be achievable because fewer healthcare resources may be required with rivaroxaban